Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global distribution and evolution of human metapneumovirus A2b2 clade: Insights from genomic surveillance.

Epidemiology and infection·2026
Same author

Author Correction: Temporal structure of natural language processing in the human brain corresponds to layered hierarchy of large language models.

Nature communications·2026
Same author

Tracheostomy in the Digital Age: How Artificial Intelligence and Immersive Technologies Are Redefining Airway Care.

Tracheostomy (Warrenville, Ill.)·2026
Same author

Global Predictors of Tracheostomy-Related Pressure Injury During COVID-19: Research Protocol.

ORL-head and neck nursing : official journal of the Society of Otorhinolaryngology and Head-Neck Nurses·2025
Same author

Temporal structure of natural language processing in the human brain corresponds to layered hierarchy of large language models.

Nature communications·2025
Same author

Magnetic decoupling as a proofreading strategy for high-yield, time-efficient microscale self-assembly.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Mar 25, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Ranolazine and Its Effects on Hemoglobin A1C.

Lindsey Greiner1, Kathryn Hurren2, Michael Brenner2

  • 1Veterans Affairs Ann Arbor Healthcare System, MI, USA lindsey.greiner@gmail.com.

The Annals of Pharmacotherapy
|February 27, 2016
PubMed
Summary

Ranolazine significantly reduced hemoglobin A1C (A1C) in type 2 diabetes patients without increasing hypoglycemia. This suggests ranolazine may benefit cardiovascular disease patients with T2DM by improving glycemic control.

Keywords:
antihyperglycemicscardiovascular drugsdiabetesdrug informationdrug trialshemoglobin A1Cliterature evaluationranolazinetype 2

More Related Videos

Author Spotlight: An Optimized Automated Method for Investigating Retinoic Acid Receptors in Neuronal Mitochondria
08:33

Author Spotlight: An Optimized Automated Method for Investigating Retinoic Acid Receptors in Neuronal Mitochondria

Published on: July 28, 2023

1.1K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K

Related Experiment Videos

Last Updated: Mar 25, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Author Spotlight: An Optimized Automated Method for Investigating Retinoic Acid Receptors in Neuronal Mitochondria
08:33

Author Spotlight: An Optimized Automated Method for Investigating Retinoic Acid Receptors in Neuronal Mitochondria

Published on: July 28, 2023

1.1K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K

Area of Science:

  • Cardiovascular Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a global health concern.
  • Effective glycemic control is crucial for managing T2DM complications.
  • Ranolazine, primarily used for chronic stable angina, has shown potential antihyperglycemic effects.

Purpose of the Study:

  • To systematically review the antihyperglycemic effects of ranolazine in patients with T2DM.
  • To evaluate the impact of ranolazine on hemoglobin A1C (A1C) levels.
  • To assess the safety profile of ranolazine regarding hypoglycemia.

Main Methods:

  • Searched EMBASE and clinicaltrials.gov for relevant studies up to December 2015.
  • Included English-language observational and randomized controlled trials.
  • Evaluated studies assessing ranolazine's effect on A1C and hypoglycemia incidence.

Main Results:

  • Seven trials (4 published, 3 unpublished) were identified.
  • Ranolazine (750-1000 mg BID) significantly decreased A1C compared to placebo (placebo-corrected change: -0.28% to -0.7%).
  • Higher achievement of A1C <7% was observed in the ranolazine group; no increased hypoglycemia risk was noted.

Conclusions:

  • Ranolazine therapy demonstrates a potential to lower A1C in T2DM patients without increasing hypoglycemia.
  • Ranolazine may offer a dual benefit for T2DM patients with chronic stable angina, addressing both cardiovascular health and glycemic control.
  • The precise mechanism of ranolazine's A1C-lowering effect requires further elucidation.